Moreover, we demonstrated that Th17/Treg ratio was associated with improved patient survival, which adds to the results from Sato et al., who have shown that a CD8/Treg ratio can be used to predict patient survival in ovarian cancer (Sato et al. 2005). The gene discussed is CD8A; the disease is ovarian cancer.